Stargardt Disease (STGD) Pipeline Analysis, 2022| Insights into the Latest FDA, EMA, and PMDA Approvals, Breakthroughs, Clinical and Non-Clinical Trials, Emerging Therapies, Treatment Algorithms, and Key Companies by DelveInsight

As per DelveInsight's assessment, globally, about 18+ key pharma and biotech companies are working on 20+ pipeline drugs in the Stargardt Disease (STGD) therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Stargardt disease has an autosomal recessive mode of inheritance associated with disease-causing mutations in the ABCA4 gene. It is both clinically and genetically highly heterogeneous. No approved treatments are available for Stargardt disease, and other therapeutic approaches do not target its root cause. There are three main avenues of intervention being explored, with human clinical trials of stem cell therapy, gene replacement therapy, and pharmacological approaches. Several research activities are underway to identify novel treatment approaches that may prove to be a way to improve the treatment scenario. Key players, such as Acucela Inc (Kubota), Alkeus Pharmaceuticals Inc, ProQR, Astellas Pharma Inc, and several others, are actively involved in developing therapies for Stargardt's disease.

"Stargardt Disease (STGD) Pipeline Insight, 2022" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Stargardt Disease Therapeutics Market.

The report provides a detailed description of the drug, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Stargardt Disease (STGD) Pipeline Analysis
The report provides insights into:
- The report provides detailed insights into the key companies that are developing therapies in the Stargardt Disease Market.
- The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Stargardt Disease treatment.
- It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Stargardt Disease market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

The Report Covers the Emerging Pipeline Products Under Different Phases of Clinical Development Like -
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage products (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates

Get Key Insights Into the Evolving Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/report-store/stargardt-disease-stgd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Stargardt Disease Therapeutics Analysis
As per DelveInsight, Stargardt Disease is anticipated to evolve immensely in the coming years owing to the rise in the geriatric population leading (which will lead to an increase in the number of people with Stargardt condition), the rise in healthcare spending across the world and the launch of the emerging therapies.

There are approx. 18+ key companies developing therapies for Stargardt disease. Currently, Belite Bio is leading the therapeutics market with its Stargardt disease drug candidates in the most advanced stage of clinical development.

Stargardt Disease Emerging Drugs
- Tinlarebant: Belite Bio
- Emixustat: Acucela Inc. (now Kubota)
- ASP7317: Astellas Pharma
- ALK-001: Alkeus Pharmaceuticals
- QR-1011: ProQR
And many more

Key Companies in the Stargardt Disease Market Include:
- IVERIC bio
- Nanoscope Therapeutics
- Alkeus Pharmaceuticals
- Kubota Vision
- Astellas Pharma
- Stargazer Pharmaceuticals, Inc.
- Belite Bio
- ProQR Therapeutics
- ReVision Therapeutics
And many others

Apart from the above-mentioned companies, there are several other prominent companies which have been focusing on the development of novel therapies for the treatment of Stargardt disease. Overall, a robust pipeline filled with novel therapies, along with the rising disease prevalence, is anticipated to boost the Stargardt Disease therapeutics market significantly.

Get a more in-depth Assessment of the Emerging Therapies and Key Companies:
https://www.delveinsight.com/sample-request/stargardt-disease-stgd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content
1. Report Introduction
2. Executive Summary
3. Stargardt Disease Current Treatment Patterns
4. Stargardt Disease - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Stargardt Disease Late Stage Products (Phase-III)
7. Stargardt Disease Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Stargardt Disease Discontinued Products
13. Stargardt Disease Product Profiles
14. Stargardt Disease Key Companies
15. Stargardt Disease Key Products
16. Dormant and Discontinued Products
17. Stargardt Disease Unmet Needs
18. Stargardt Disease Future Perspectives
19. Stargardt Disease Analyst Review
20. Appendix
21. Report Methodology
*The table of contents is not exhaustive; the final content may vary.

Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/stargardt-disease-stgd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com
Request for Sample Copy of the Report at:
https://www.delveinsight.com/sample-request/stargardt-disease-stgd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.